Jade Biosciences (NASDAQ:JBIO) Raised to “Strong-Buy” at Lifesci Capital

Jade Biosciences (NASDAQ:JBIO) was upgraded by Lifesci Capital to a “strong-buy” rating in a research note issued on Friday,Zacks.com reports.

Several other brokerages also recently commented on JBIO. Stifel Nicolaus set a $40.00 price target on shares of Jade Biosciences in a report on Friday. Weiss Ratings reissued a “sell (e+)” rating on shares of Jade Biosciences in a research note on Monday, December 29th. HC Wainwright initiated coverage on Jade Biosciences in a research report on Wednesday, January 7th. They set a “buy” rating and a $25.00 target price for the company. Guggenheim upped their target price on Jade Biosciences from $14.00 to $17.00 and gave the company a “buy” rating in a research note on Tuesday, November 18th. Finally, Wall Street Zen upgraded Jade Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $24.00.

Jade Biosciences Trading Up 1.2%

Shares of JBIO opened at $14.05 on Friday. The business’s 50 day moving average is $14.78 and its 200 day moving average is $11.92. The company has a market capitalization of $692.81 million, a PE ratio of -3.05 and a beta of 1.03. Jade Biosciences has a 12-month low of $6.57 and a 12-month high of $100.10.

Jade Biosciences (NASDAQ:JBIO) last posted its quarterly earnings data on Friday, March 6th. The company reported ($0.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.34.

Institutional Investors Weigh In On Jade Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in JBIO. Geode Capital Management LLC bought a new position in Jade Biosciences in the 2nd quarter worth about $6,759,000. Police & Firemen s Retirement System of New Jersey bought a new stake in shares of Jade Biosciences during the second quarter valued at approximately $71,000. Intech Investment Management LLC purchased a new stake in shares of Jade Biosciences in the second quarter valued at approximately $230,000. Versant Venture Management LLC purchased a new stake in shares of Jade Biosciences in the second quarter valued at approximately $15,243,000. Finally, JPMorgan Chase & Co. bought a new position in Jade Biosciences in the second quarter worth approximately $154,000.

About Jade Biosciences

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.